Illumina (ILMN) Soars 23.4% on Earnings Beat

Core Insights - Illumina, Inc. (NASDAQ:ILMN) experienced a significant stock price increase of 23.4% week-on-week after surpassing earnings guidance for Q3 and projecting a smaller revenue decline for fiscal year 2025 [1][2] - The company reported a net income drop of 79% to $150 million from $705 million, while revenues remained flat at $1.08 billion [1] Financial Performance - Illumina's Q3 results exceeded the high-end of revenue and earnings guidance, driven by growth in the clinical segment, which is its largest market [2] - For fiscal year 2025, Illumina now anticipates a revenue decline of only 0.5% to 1.5% year-on-year, a revision from the previous upper range of 2.5% [2] Company Overview - Illumina is a leading genomics company specializing in DNA sequencing and array-based technologies for various applications, including life sciences, oncology, and reproductive health [2]